| Ms Janice L Barkley, MA | |
|
509 Crossway Avenue, Barkley And Associates Inc, Murfreesboro, TN 37130 | |
| (615) 895-3977 | |
| (615) 895-9219 |
| Full Name | Ms Janice L Barkley |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 509 Crossway Avenue, Murfreesboro, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083781728 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Janice L Barkley, MA Po Box 2249, Barkley And Associates Inc, Murfreesboro, TN 37133-2249 Ph: (615) 895-3977 | Ms Janice L Barkley, MA 509 Crossway Avenue, Barkley And Associates Inc, Murfreesboro, TN 37130 Ph: (615) 895-3977 |
News Archive
Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.
The World NET Community announces the first Worldwide NET Cancer Awareness Day on November 10, 2010 to raise awareness about cancers called neuroendocrine tumors (NETs) and the need for timely detection and diagnosis. More than 90% of all NET patients are incorrectly diagnosed and initially treated for the wrong disease. Misdiagnoses or delayed diagnoses mean that NET patients are treated on average five to seven years for the wrong disease; often the correct diagnosis is not made until the disease has spread (metastasized).
Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. The study demonstrated that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
› Verified 6 days ago